Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,279,889 B2 for its innovative catheter-based platform technology. The patent covers advanced systems for locating, monitoring, and mapping electrophysiological signals during neuromodulation procedures.

The technology features a catheter-based microchip sensing array antenna designed to detect neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. Key applications include chronic pain management, hypertension treatment, and cardiac modulation. The company plans to submit an IDE and begin U.S. clinical trials in 2025 for pancreatic cancer pain treatment.

Positive

• None.

Negative

• Product still requires FDA approval through clinical trials
• Commercialization timeline extends into future years

Insights

Medical Technology Patent Expert

Autonomix's new patent strengthens IP position in nerve-sensing technology, enhancing commercialization prospects for pain management applications.

Autonomix Medical's newly granted patent (U.S. Patent No. 12,279,889 B2) represents a significant enhancement to their intellectual property portfolio, which now includes over 80 issued patents. The patent specifically covers advanced systems for locating, monitoring, and mapping electrophysiological signals during neuromodulation or denervation procedures—core capabilities for their catheter-based microchip sensing platform.

The technology described includes several critical innovations: microneedle-integrated sensors for deep tissue access, multiband optical sensors, microfingers for distributed sensing, and automated treatment adjustment systems. These components enable Autonomix's "sense, treat, and verify" approach to nerve-targeted treatments, potentially offering superior precision compared to existing technologies.

From a commercialization perspective, this patent strategically positions Autonomix in the growing nerve-focused therapeutics market, addressing multiple high-value indications including chronic pain management, hypertension treatment through renal denervation, and cardiac modulation. The company's planned IDE submission and clinical trials in 2025 for pancreatic cancer pain treatment represent their first commercial pathway, targeting a condition with limited effective treatment options beyond opioids and invasive procedures.

This patent issuance enhances Autonomix's competitive moat in a specialized medical device segment where intellectual property protection is crucial for maintaining market advantage and supporting future licensing or partnership opportunities.

Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications

Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents

THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,279,889 B2 (the ‘889 patent) titled, “Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification.” The newly issued ‘899 patent relates to but is not limited to advanced systems and methods for locating, monitoring and mapping electrophysiological signals before, during and following a neuromodulation or denervation procedures. Furthermore, the patent explicitly contemplates tools to access small vessels and navigation to the target area to treat cancerous tumors and the pain associated with cancerous tumors. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders.

“This granted patent represents a significant step forward in our mission to improve patient outcomes by delivering more effective, less invasive treatments for conditions involving the nervous system, including chronic pain, autonomic dysfunction associated with hypertension and a range of other nerve-related disorders. We are pleased to strengthen our IP portfolio and further enhance our intellectual property position in the rapidly growing nerve-focused therapeutics space, enabling us to protect our innovations and deliver improved solutions for both clinicians and patients,” commented Brad Hauser, CEO of Autonomix.

In particular, the ‘899 patent describes the Autonimix technology including, but not limited to: use of sensors integrated into microneedles for deep tissue access; multiband optical sensors for tissue viability and tone; microfingers for gentle, reliable contact and distributed sensing; and control systems that automatically adjust treatment based on feedback signals.

Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

The Company expects to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.

For more information about the Company’s technology, please visit autonomix.com.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, and timing of its submission of an IDE and the commencement of U.S. clinical trials. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com

FAQ

What is the new patent granted to Autonomix Medical (NASDAQ: AMIX)?

Autonomix received U.S. Patent No. 12,279,889 B2 for systems and methods for neurological traffic evaluation and modification, featuring advanced catheter-based technology for nerve sensing and treatment.

How does Autonomix Medical's (AMIX) nerve sensing technology work?

The technology uses a catheter-based microchip sensing array antenna to detect neural signals, combined with RF ablation technology for precise nerve treatment.

What medical conditions can Autonomix Medical's (AMIX) technology treat?

The technology is designed to treat chronic pain, hypertension, cardiac conditions, and various neurological disorders influenced by sympathetic nerve activity.

When will Autonomix Medical (AMIX) begin clinical trials?

Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025, initially focusing on treating pancreatic cancer pain.

What advantages does Autonomix Medical's (AMIX) technology offer over current treatments?

The technology offers greater precision and sensitivity compared to current treatments like opioids or invasive ethanol injections, potentially providing better outcomes with fewer side effects.